Podcasts about Charu

Jewelry Business Academy Podcast

Play Episode Listen Later Oct 10, 2024 37:10

Alison Mitchell is alongside Charu Sharma and Jim Maxwell to discuss the effects on women's cricket in Bangladesh, with the country not hosting the Women's ICC T20 World Cup. Bangladesh cricket writer Tawhid Qureshi gives his thoughts on how the domestic game in Bangladesh would have benefited from the spotlight that hosting a World Cup brings, and how Bangladeshi players need more pathways to the professional game.Ali, Jim & Charu reflect on Joe Root becoming England's men's leading run-scorer in Tests and on his compatriot Harry Brook scoring a triple century in the first Test in Multan against Pakistan.Plus, they find out more about cricket's inventors and innovators by talking to Stuart Robertson – the inventor of T20 cricket.

women england world cup tests pakistan rewards hosting bangladesh reap bangladeshi t20 t20 world cup joe root multan charu harry brook alison mitchell jim maxwell charu sharma

166 | I'm Finally Doing What I Was Born to Do: The Highs, Lows, and Lessons of Launching My Jewelry Business with Charu Boeckel

Play Episode Listen Later Oct 5, 2024 59:50

Whether you're looking to launch your own jewelry business or you're already navigating the challenges and seeking motivation to stay on track, this episode is tailor-made for you! In this episode, I sit down with Charu Boeckel, the incredible founder of Amuleto, to dive deep into her journey as a jewelry designer. Charu has been in the jewelry world for over 14 years, but her path wasn't always so clear. She shares how she made the bold transition from finance to fashion, stepping into a world that allowed her to truly express herself. Charu talks about the challenges she faced while building her own brand and the power of community in overcoming imposter syndrome, something many of us can relate to. Charu reflects on how her brand is about so much more than just jewelry—it's about connecting with our divine selves. Her story is a reminder of the ups and downs of entrepreneurship and the personal growth that comes from facing those challenges head-on. If you're an entrepreneur, creative, or someone seeking more purpose in your work, this conversation will resonate deeply with you. Join us as Charu opens up about the reality of building something meaningful and finding your own path along the way. Topics Discussed Navigating Imposter Syndrome in Business Building a Community and Engaging Customers Overcoming Manufacturing Challenges The Meaning Behind Amuleto Jewelry __________________________ Ready to change your life? Download your FREE training: Click here to watch your FREE training video from Robyn and learn the 6 steps that'll change your biz & life, fast. __________________________ Ready for Growth? Then This Invitation is for You: If you're looking for my support on how to scale your jewelry business, join the Jewelry Business Academy. This is the most expansive and supportive container for jewelry business owners who want to scale to 6+ figures without burning out. You'll get my eyes on your business every single week, as well as lots of 1:1 support, and will join a community of jewelry business owners all scaling their businesses together. I've helped jewelry business owners from around the world, from those just starting out to those making multiple six-figures, build solid foundations, find clarity, implement systems and proven growth strategies, and hit big goals. I want to help you do the same. Learn more here: jewelrybusinessacademy.ca __________________________ Connect with Us: Follow Robyn on Instagram: @RobynClarkCoaching Join the Jewelry Business Academy: Jewelry Business Academy __________________________ Subscribe & Review: If you enjoyed this episode, please subscribe and leave a review on your favorite podcast platform. Your support helps us reach more jewelry business owners like you! __________________________ LINKS MENTIONED: Instagram: https://www.instagram.com/divineamuleto/ Website: https://www.divineamuleto.com/

community lessons growth entrepreneur mindset motivation startups launching women in business business strategy jewelry business lessons business building highs lows charu business launch amuleto

Jason Gillespie on putting faith in his Pakistan players

Play Episode Listen Later Oct 3, 2024 36:55

Alison Mitchell is alongside Charu Sharma and Jim Maxwell to discuss Pakistan hosting England in a three-test series, which begins on 7 October.Alison speaks to Pakistan red-ball head coach Jason Gillespie ahead of the series with the new coach looking to turn around Pakistan's fortunes, with just two wins in their last thirteen Tests. He talks about wanting to instill belief in his squad, as well as managing his captain Shan Masood and improving the squad's fitness.Plus, Ali, Jim & Charu find out the origin of one of cricket's iconic techniques - the ‘Googly'.Photo Credit: Pakistan men's test team head coach Jason Gillespie speaks to the media at National Bank Cricket Stadium on July 07, 2024 in Karachi, Pakistan. (Photo by Muhammad Sameer Ali/Getty Images).

england putting players tests pakistan karachi charu googly jason gillespie alison mitchell jim maxwell shan masood charu sharma

The Biggest Mistake I've made in relationships...

love relationships lifetime biggest mistakes charu pretty please

Play Episode Listen Later Sep 11, 2024 39:14

I'm a genuinely kind and loving person. I have great capacity for clear communication and I have done SO SO SO much 'inner work'.... what could possibly be going wrong in my relationships? Well, in this episode, I'm gonna tell you. This is a great episode for anyone who can relate to having done all that 'work', anyone who may feel they are the more 'skilled' partner in their relationships (I'm including family and friends as well as intimates here). It's also for anyone who may be feeling tired of bearing the weight of always being the 'bigger person'. This can be one of the most difficult patterns to see because we may feel like we are serving the relationship, but we are actually stopping the potential for true intimacy. I share a lot of my personal story in this episode, I hope it helps to highlight and educate if you have found yourself in similar relating patterns. Please let me know if you listen and it has value for you. Making a podcast is one of my favorite things I have done, but it is also so strange to be creating and sharing into blackness. While hundreds of you listen, all I get to see are numbers on an analytics page... it's just me, alone in a room, talking about a thing I hope provides insight and value for you. Anytime you write a review, leave me 5 stars or comment on my social media, it genuinely creates the inspiration to keep going. I have so much inside of me to share with you, so much I have cultivated from a literal LIFETIME of study of our human behavior. It flows out of me with joy when I feel how it's supporting you. So, thank you to those who have shared your experience with me and a big PRETTY PLEASE keep sharing with me what you are receiving and what you would like to hear more about! Means the world to me. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Find out more about working one-on-one with Charu at charumorgan.com/sessions ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours. For more information on small group retreats and online courses go to: www.CharuMorgan.com

An outside of the box sensual exploration to expand your experience of sex.

love expand exploration sensual charu

Play Episode Listen Later Sep 5, 2024 31:30

What has shaped your sex life? The WAY you make love? What if there is territory yet to be explored that you haven't accessed only because it never occurred to you to approach your partner in new ways? In this episode I speak in detail about some very simple things you can try with your lover to incorporate their whole body and expand the possibilities for pleasure for both of you. Can't wait for you to listen and then try it! Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Find out more about working one-on-one with Charu at charumorgan.com/sessions ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours. For more information on small group retreats and online courses go to: www.CharuMorgan.com

The single most important thing that affects your sex-life and relationships.

love relationships single sex life charu

Play Episode Listen Later Aug 28, 2024 31:49

Do you find yourself experiencing the same things in relationship even with different partners over time? Are you having the same fight over and over with your partner? Are you noticing the overlap between how you felt within a family dynamic happening in your romantic relationship? This is so so normal... in fact, perhaps part of intimate relationship is experiencing similar things that we once faced in childhood and having the opportunity to grow and make different choices. In this episode, I talk about what is at the core of these repeating patterns and some super simple steps you can take to begin to strengthen and mature within relating. Within the episode you will find a lot of care and tenderness for the parts of us that have decided all the many things we need to do to be loved. I hope you will carry that tenderness with you as you explore within yourself once you've listened. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Find out more about working one-on-one with Charu at charumorgan.com/sessions ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours. For more information on small group retreats and online courses go to: www.CharuMorgan.com

20240720 || Address - Bhakti Charu Swami Mahārāja Tirobhāva Mahotsava || Śrī Māyāpur, India

Jayapataka Swami Archives

Play Episode Listen Later Aug 22, 2024 27:20

address swami bhakti charu

What makes you worthy of love? An episode for those who need to be needed.

Play Episode Listen Later Aug 15, 2024 20:08

Does it ever feel like some of the relationships in your life just drain you? Like somehow you feel better when you are away from that family member, friend or partner...even though you love them so so much? Maybe you even feel like your bond with this person is so special and the kind of intimacy you have with them is like no other... even though you can't shake the drained feeling? I get it. In this episode we talk about some of the very good reasons you might be feeling this way. It may be tied into a deeper belief... Some of us have built our lives and intimate relationships around how good we are at giving people what they need. It's a beautiful quality and it can also bring some complex challenges when a situation isn't well-balanced. This episode deep dives into what underlying internal things may be going on here, how to become aware of them and how to work with them. If you resonate with what I'm speaking to here, I hope this paves the way for more reciprocal bonds in your future. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Find out more about working one-on-one with Charu at charumorgan.com/sessions ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours. For more information on small group retreats and online courses go to: www.CharuMorgan.com

love worthy charu

The Seasons of Relating

Sacinandana Swamis Podcast

Play Episode Listen Later Aug 11, 2024 25:32

Long-term relationship. It sure does have it's ups and downs. We all know that's kinda to be expected… ..and yet the thing I hear the most is ‘we've lost our spark'… followed by a lot of comparison to what they once had or what other couples have. It's so so normal to think something is WRONG when our sexual connection changes… and to try to get back that ever-elusive ‘spark'. I'm here to share a different message. I see relationships as having seasons. Trying to create a summer spark in the middle of a winter season is missing the possibility for the wisdom that winter is bringing… including the invitation to deeper experiences in lovemaking. In this episode I'm talking about why we have an obsession with an endless summer and how to sink into the beauty of all the seasons. Click these links to listen: APPLE . SPOTIFY Pretty please, wherever you get your podcasts… if you enjoy this episode: FOLLOW, GIVE IT 5 STARS, LEAVE A REVIEW, SHARE WITH A FRIEND... all the things!! I genuinely could use some community support making sure the work I do gets seen in this wacky world. If it has been valuable to you, and it's authentic for you to share, that would mean so much to me! love- Charu P.S. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Interested in working with Charu 1 on 1? Find out more information at charumorgan.com/sessions Learn more at www.CharuMorgan.com where you can find information on working with me in small group retreats and online courses. ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours.

love apple stars relating charu

Remembering Bhakti Charu Swami

Play Episode Listen Later Aug 10, 2024 42:38

2024.07.04 Gaura Bhavan EN

swami bhakti charu

The exquisite possibilities in lovemaking

love possibilities addition exquisite lovemaking charu

Play Episode Listen Later Jul 30, 2024 44:34

What if there is a whole world to lovemaking that most of us are not even aware of? Something that takes the experience in a completely direction. What if lovemaking could arise from expansion, relaxation and unfolding? What if the stories we have been told about a hard cock and a tight pussy being the best of the best when it comes to sex actually don't include the whole picture? How might that change the way we make love? How might that change the way we relate to our bodies? Our lovers? There is an incredible landscape just waiting to be discovered in sex. It isn't instead of what we already know, it's in ADDITION to. It is rich, it is deep, it is sublime. In this episode, I begin to invite you into that space of possibility. I hope it inspires you. You might find what I share hard to believe, but I promise every word is true. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Learn more at www.CharuMorgan.com where you can find information on working with me 1 on 1 as well as small group retreats and online courses. ***We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours.

Your relationship is a living breathing entity…. Have you been forgetting to feed it?

love relationships forgetting entity charu living breathing

Play Episode Listen Later Jul 12, 2024 39:36

What does it take to grow in love and sex within your partnership? No one has talked to us about what it actually takes to have a partnership that really lights us up and keep us excited and inspired....and yet, that's what so many of us long for. It's like a destination we crave, but we have no map. In this episode we talk about: What we have been prioritizing and why (and how it may be taking us away from the connection). A simple scaffolding to help hold us as we journey back towards our partner. The easiest steps to take to re-invest in our love. The journey to creating a truly fulfilling partnership is deep and sometimes complex... listening to this episode and beginning to turn towards this inquiry and exploration is a great way to begin. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Learn more at www.CharuMorgan.com where you can find information on working with me 1 on 1 as well as small group retreats and online courses. AND....We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours.

What a French election upset means for the Euro

Play Episode Listen Later Jul 8, 2024 23:04

In today's episode, Charu Chanana is back in the studio talking macro and forex with Søren Otto. They will discuss the surprising outcome of the French election and what it means to the EUR. Charu will also touch up Friday's US nonfarm payroll, the UK election and a quick preview of the upcoming Royal Bank of New Zealand meeting. Read daily in-depth market updates from the Saxo Market Call and SaxoStrats Market Strategy Team here. Click here to open an account with Saxo.

uk french new zealand euro upset eur royal bank french elections saxo charu

Politics are taking over macro

Play Episode Listen Later Jul 1, 2024 22:32

In today's episode, Charu Chanana is back in the studio talking macro and forex with Søren Otto. And not just macro, but also politics as this is the prime focus area for markets. Not only did we have the first debate between the two US presidential candidates last week, we also had the first part of the French election and in the coming week, the UK will hand in their votes. Listen to Charu's takes on it all in this episode. Read daily in-depth market updates from the Saxo Market Call and SaxoStrats Market Strategy Team here. Click here to open an account with Saxo.

uk politics french macro saxo charu

Porn: creating inspiration or disconnect?

love inspiration porn investigating disconnect charu

Play Episode Listen Later Jun 27, 2024 31:57

The topic I've been asked to speak about the most since I started this podcast is PORN. Before I even begin to explore this topic, I want to be very clear that I am NOT against porn. The view I hold is that the most important thing is… what does your relationship to porn feel like for you? Is it creating inspiration and bringing things to you and your partner or is it taking something away? Over the years I have worked with many clients who have felt lost and distant from a partner who is consumed by porn or clients who have partners mimicking what they have seen in porn in the bedroom and it just isn't creating fulfillment or satisfaction. In this episode we explore: *Investigating whether porn is bringing inspiration or disconnect in your life. *How to create productive conversations with your partner about how your relationship to porn feels for them. *How porn may be affecting your arousal response and why. *How to begin to explore bringing vitality into the whole body rather than everything being head/fantasy-centered. Ultimately, it's possible that your relationship to porn may be limiting the depths of pleasure and exploration you can experience with your partner. This is not about making porn ‘good' or ‘bad', it's about allowing for as much exploration and curiosity as possible. Do you see yourself in these episodes? Want some additional support? I would absolutely LOVE to be a part of your journey! Learn more at www.CharuMorgan.com where you can find information on working with me 1 on 1 as well as small group retreats and online courses. AND....We've also created something special for you! If you would like to get started with some of the movement and breath that Charu speaks about in these episodes, you can get a FREE Start-up kit with videos for solo practice & a full-length class to do if you have a partner! Go to www.charumorgan.com/startup to get yours.

Is it time to diversify your portfolio?

Play Episode Listen Later Jun 24, 2024 26:04

In today's episode, Charu Chanana is back in the studio talking macro and forex with Søren Otto. They discuss the current equity rally and Charu gives her thoughts on what may derail it and ponder over how investors may position to protect their portfolio. They also discuss JPY, an interesting host of central bank meetings last week and why political risk may be greater in the coming week than economic risk. Read daily in-depth market updates from the Saxo Market Call and SaxoStrats Market Strategy Team here. Click here to open an account with Saxo.

diversify saxo charu jpy

It is rate cut week

Play Episode Listen Later Jun 3, 2024 20:26

In today's episode, Charu Chanana is back in the studio talking macro and forex with Søren Otto. ECB will cut rates on Thursday, and is the big story this week. But it may not be the only rate cut this week, as the Bank of Canada may do the same. We will also get a fair bit of US data and the Swiss Franc is in focus. This - and more - is what Charu and Søren will talk about. Read daily in-depth market updates from the Saxo Market Call and SaxoStrats Market Strategy Team here. Click here to open an account with Saxo.

canada bank ecb rate cut saxo charu swiss franc

Up in your partner's business... when you know all the things they are doing wrong and if they just fixed them your relationship would be perfect.

relationships partner diving charu

Play Episode Listen Later Apr 19, 2024 23:40

1. Yay for our first episode!! Diving into podcasting with a crappy mic, but some great insights! In this episode we talk about: - What we tend to do in relationships that makes them more difficult. - Things we may be doing to escalate challenges with our partner unconsciously. - What you CAN do instead of trying to change your partner's behavior. - One reason your partner is so reactive when you have constructive criticism. - How to navigate what happens next when this thing your partner is doing won't change. Do you see yourself in this episode? Want some additional support? Learn more about Charu's work at www.CharuMorgan.com where you can find information on working with her 1 on 1 as well as small group retreats and online courses. Charu Morgan has spent the last 20 years in deep devotion and exploration of all things relating. She has worked with thousands of clients, supporting them in feeling more alive in their bodies, more integrated in their sexual experiences and closer to the ones they love.

What every 20-something woman should know about perimenopause

Hush Podcast

Play Episode Listen Later Apr 16, 2024 27:35

Many are aware of menopause, but have you heard of perimenopause? In this episode of Hush, we delve into the often lesser-known stage of perimenopause, which can start as early as your 20s?! From understanding what perimenopause entails to navigating its symptoms, the girls and their guests, Dr Charu from International Medical Clinic Katong and Nicia, one of the girls behind Instagram community that aims to spark conversations among Peri-Menopausal Women, @beyondthepause_sg, are going to equip you with essential insights every 20-something woman (and the people around them!) should know. Watch this episode on YouTube: https://youtu.be/2ES_kat512ESee omnystudio.com/listener for privacy information.

health woman menopause hush perimenopause women podcasts women health charu

Who is the toughest player in men's cricket?

WOAFM99 Radio Show with Oliver Sean

Play Episode Listen Later Apr 11, 2024 32:08

Charu Sharma, Jim Maxwell and Nikesh Rughani are joined by Richard Sydenham who has written a book exploring what makes a cricketer tough and the physical and psychological aspects of it. He shares the stories from former players and what helped inform his 22 player list. Plus the Stumped team devise their own list. 21 year old Mayank Yadav won the player of the match award on his IPL debut for Lucknow Super Giants. Charu and Nikesh debate if he should be picked in the India T20 World Cup squad and the pressures surrounding the young player. Photo: Australian cricketer Steve Waugh during the 4th Test Match between the West Indies and Australia in Jamaica, May 1995. (Photo by Clive Mason/Getty Images)

australia player jamaica cricket toughest west indies ipl stumped test match charu steve waugh nikesh jim maxwell lucknow super giants charu sharma nikesh rughani

Unraveling the Rhythms of Raga Jazz with Award-Winning Artist Charu Suri on WOAFM99

Play Episode Listen Later Mar 23, 2024 58:32 Transcription Available

Dive deep into the captivating world of Raga Jazz in this special episode of WOAFM99 featuring renowned musician and New York Times journalist, Charu Suri, who is chatting with WOAFM99 celebrity host - MTV EMA Nominated Artist/Producer and former MTV VJ Oliver Sean. Discover Charu's unique blend of musical traditions from the East and West, and travel through her awe-inspiring career - from her fourth concert at Carnegie Hall to touring the UK, to planning an imminent tour in India. Not only will you get to hear an exclusive interview with Charu, but also enjoy a brilliant line-up of indie songs, from a range of talented artists - from Ashton Elvis's fantastic new music video hit single, to the upbeat rhythm of The Silvers' track. We also bring you a new Blues single by Laura Vida, and the band Wikked Nights take you back to the 80's rock scene. There is a brilliant chill out genre single by Mark Driver, an inspiring country song by David Scott Weaver, and a heart wrenching song by Jenalen . Each track is meticulously selected to complete a sonic journey that's sure to bedazzle your senses. Uncover the valiant DIY philosophy of independent artists and their commendable ability to hold their own against music industry giants. Hear more about our WOA Music Awards that honor these audacious independent artists and their extraordinary passion for music. Special guest Charu Suri further elaborates on the therapeutic influence of Raga Jazz, enlightening listeners on how this genre's unique sounds bring a range of benefits. Hear about her globally successful album 'Rags and Raga,' an ode to her love for New Orleans Jazz, including a taste of the mesmerizing Bourbon Street Stroll track. Additionally, takeaway insights from her previous career as an award winning journalist at the New York Times, and her method of fusing this with her musical passions through her Substack posts. www.woaentertainment.com www.oliversean.com

uk new york times west artist dive east blues jazz diy uncover substack award winning unraveling rhythms carnegie hall suri silvers raga new orleans jazz charu

Rainbows & Holi! (with Charu Suri)

Ear Snacks

Play Episode Listen Later Mar 22, 2024 33:52

Why ARE there so many songs about rainbows? Because there's SO MUCH TO SAY about them! Andrew & Polly act as the prism for some awesome tangential concepts connected to ROY G BIV. Jazz piansit Charu Suri shares the connection between raga (Sanskrit for "color" or "dye") and the aura of music, as well as her love of the mischievously vibrant paint-throwing Festival of Colors, Holi! And Nina Silver takes us on a guided unpacking of flood myths and rainbows as symbols of hope in a sonically rich imagining of Noah's Ark at the Skirball Cultural Center. In this episode, you'll hear: Rainbow Shoppe by Andrew & Polly (feat. Lucy Kalantari) Bourbon Street Stroll (Raga Hemant) by Charu Suri from Rags & Ragas Aaj Rang Hai (Today There is Color) by Charu Suri from The Book of Ragas (Vol. 2) additional underscore by Andrew & Polly You can hear more colorful bops on our Spotify Playlist: (So Many) Songs About Rainbows Many thanks to Charu, Nina, and our friends Adrian, Stella Rose, Townes, and Tenny (and their parents & siblings) for sharing what they know about rainbows! If you know a kid who has something to say (spoiler alert: they all do!), to learn more or to be on the show, visit earsnacks.org

festival color jazz ark colors rainbows sanskrit rags holi suri townes charu roygbiv tenny skirball cultural center stella rose

Intimacy After Sexually Transmitted Infections with Dr. Charu Ramaprasad

The Muslim Sex Podcast

Play Episode Listen Later Mar 22, 2024 36:37

On this episode, Dr. Sadaf Lodhi chats with Dr. Charu Ramaprasad about everything you need to know about intimacy after sexually transmitted infections (STIs). Dr. Charu Ramaprasad is an infectious diseases physician and during this discussion, she shares her expertise on everything from HIV to gonorrhea, chlamydia, syphilis, and herpes. Learn about the importance of STI testing, the latest advancements in treatments, and so much more on this empowering and hopeful discussion on taking back your sexual health!Disclaimer: Anything discussed on the show should not be taken as official medical advice. If you have any concerns about your health, please speak to your medical provider. If you have any questions about your religion, please ask your friendly neighborhood religious leader. It's the Muslim Sex Podcast because I just happen to be a Muslim woman who talks about sex.To learn more about Dr. Sadaf's practice and to become a patient visit DrSadaf.comLike and subscribe to our YouTube channel where you can watch all episodes of the podcast!Feel free to leave a review on Apple Podcasts and share the show!Follow us on Social Media...Instagram: DrSadafobgynTikTok: DrSadafobgyn

social media muslims intimacy hiv sti stis sexually transmitted infections charu sadaf sadaf lodhi

Percy Jackson “A Half-Blood Christmas” (w/ Little #1)

Totally Rad Christmas!

Play Episode Listen Later Feb 12, 2024 39:04

What's up, dudes? Christmas in the Underworld was NOT my idea! That's right! It's a Percy Jackson Christmas in this bonus episode with my daughter, Little #1! We get into two PJ short story adventures!In “The Sword of Hades,” the demigod children of the Big Three—Zeus, Poseidon, and Hades—are gathered in the Underworld by Persephone. Percy, Thalia, and Nico use an enchanted flower to follow a thief and retrieve Hades's newly forged sword. They fight off Keres, Melinoë the goddess of ghosts, and the Titan Iapetus. The trio retrieve the sword, even if the Underworld didn't get into the Christmas spirit. On December 18, 2020 in La Repubblica, Riordan published “Un Natale Mezzosangue.” Percy and Nico shadow travel to Florence during the pandemic to find a perfect gift for Annabeth. They find the shop of the last Etruscan god Charu. He gives Percy a magical bracelet in exchange for the answer to a question. Percy's answer—that Christmas is for everyone, especially in times of difficulty—placates the deity. Nico and Percy head back to New York with a perfect gift!Titans? Check. Gods? Yep. Cheeseburgers? Only from McHale's! So grab Riptide, put on your Camp Half-Blood t-shirt, and shadow travel to a Percy Jackson Christmas!Check us out on Facebook, Twitter, Instagram, Totally Rad Christmas Mall & Arcade, Teepublic.com, or TotallyRadChristmas.com! Later, dudes!

9926 Jill Nicolini Interviews Charu Puri Intuitive Counsellor, Yoga Teacher and Founder of A Modern Yogi

Podcast Business News Network Platinum

Play Episode Listen Later Jan 5, 2024 29:34

https://amodernyogi.ca/ Listen to us live on mytuner-radio, onlineradiobox and streema.com (the simpleradio app)https://onlineradiobox.com/search?cs=us.pbnnetwork1&q=podcast%20business%20news%20network&c=ushttps://mytuner-radio.com/search/?q=business+news+networkhttps://streema.com/radios/search/?q=podcast+business+news+network

founders modern intuitive yogi yoga teachers counsellor puri charu

9886 Jill Nicolini Interviews Charu Puri Intuitive Counsellor, Yoga Teacher and Founder of A Modern Yogi

Podcast Business News Network Platinum

Play Episode Listen Later Dec 29, 2023 26:09

founders modern intuitive yogi yoga teachers counsellor puri charu

The Best of Stumped in 2023

Podcast Business News Network Platinum

Play Episode Listen Later Dec 28, 2023 35:52

Please note: This programme contains discussions about alcoholism and references to mental health. If you are suffering distress or despair and need support, you could speak to a health professional, or an organisation that offers support. Details of help available in many countries can be found at Befrienders Worldwide. www.befrienders.orgWe look back at the best of Stumped in 2023. This is another chance to hear some of the standout moments from 2023 including a powerful interview from South Africa wicketkeeper Sinalo Jafta. She entered rehab after battling with her alcohol addiction and won a runners up World Cup medal only a few months later.You can listen back to our trip to Mumbai for the inaugural Women's Premier League and Charu's interview with Delhi Capitals and India player Shikha Pandey. She tells us of the new talent emerging in the country.Australia won the Men's 50 Over World Cup in India thanks largely to their captain Pat Cummins. Cummins has been Australia skipper for 18 months now and we hear from his former teammate Trent Copeland.Stumped also returns to Lord's when Alison Mitchell, Jim Maxwell and Sunil Gupta spoke to former Australian coach Justin Langer who told us about his memories of playing at the home of cricket. Plus we hear from the creator of the viral cricket episode of Bluey and enjoy a classic Stumped debate on the use of red cards.Photo: India's Shikha Pandey (L) celebrates with teammate India's Richa Ghosh (R) after the dismissal of Australia's Beth Mooney (not seen) during the semi-final T20 women's World Cup cricket match between Australia and India at Newlands Stadium in Cape Town on February 23, 2023. (Credit: AFP via Getty Images)

9850 Jill Nicolini Interviews Charu Puri Intuitive Counsellor, Yoga Teacher and Founder of A Modern Yogi

Play Episode Listen Later Dec 26, 2023 27:32

founders modern intuitive yogi yoga teachers counsellor puri charu

Charu Mishra | The world's foremost expert on snow leopard conservation

Conservation Careers Podcast

Play Episode Listen Later Dec 4, 2023 64:02

We ran a live event in partnership with Conservation Optimism, to explore and celebrate the work of Dr Charu Mishra - the world's foremost expert on snow leopard conservation, and double Whitley Gold Award Winner. Conservation Optimism is a global community dedicated to inspiring people to make a positive difference for nature, and co-hosting the live event with me was Sofia Castelló y Tickell. Together we spoke to Charu, who is the Executive Director of the International Snow Leopard Trust and Co-Founder of India's Nature Conservation Foundation. He's spent 25 years working to increase protection for snow leopards across all 12 of their range countries, with the vital support of local people, and has won the Whitley Gold Award in 2005 and in 2022. As a world expert on snow leopard conservation he has pioneered the community-based conservation approach to enable harmonious co-existence between people and wildlife. Sofia and I talked to Charu about his work as Executive Director of the International Snow Leopard Trust, and his approach to community-based conservation. We also explore his career path, his careers advice for aspiring conservationists, and also what keeps him optimistic about the future. Finally, we also discuss the importance of ethics in wildlife conservation and the Ethical Conservation Alliance which he launched recently at the Whitley Fund for Nature, People for Planet Summit. Towards the end of the recording, we also open up to our audience where they get the opportunity to ask their questions of Charu. It's a wide-ranging, snow-leopard-conservationing, and humbly-inspiring pod-chat. Enjoy.

career nature co founders executive director cats ethics communities indigenous conservation wildlife foremost mishra snow leopards charu tickell

1196: Mental Hygiene / An Interview with Yogi Charu

Wisdom of the Sages

Play Episode Listen Later Nov 19, 2023 59:22

Raghunath and Kaustubha interview their longtime friend, Yogi Charu, about the importance of maintaining a daily sadhana and other practices for physical, spiritual and mental health. Check out Charu's book, https://a.co/d/3L4z0zB Learn more about Yogi Charu and his latest offerings at https://www.yogicharu.com/

yogi mental hygiene charu raghunath

1196: Mental Hygiene / An Interview with Yogi Charu

Wisdom of the Sages

Play Episode Listen Later Nov 19, 2023 59:22

yogi mental hygiene charu raghunath

S12E11: Day in the Life of a Kearney Strategic Operations Intern

Strategy Simplified

Play Episode Listen Later Nov 17, 2023 33:21

Charu Goyal joined the pod to chat through her MBA decision process, experience as a Kearney summer intern, why she chose Kearney, and more:The training Kearney offers internsKearney's core valuesA day-in-the-life of an MBA internThe skills consulting gave CharuKearney's application deadline for the Summer Associate role for 1Y MBAs is December 1, 2023. Apply here.Relevant LinksConnect with Charu on LinkedInLearn more about KearneyBuild your firm's brand awarenessConnect With Management Consulted Follow Management Consulted on LinkedIn, Instagram, and TikTok for the latest updates and industry insights. Join the next Extreme Consulting Makeover - every Tuesday at 12pm ET! Email our team (podcast@managementconsulted.com) with any questions or feedback. Sponsor an episode or advertise on Strategy Simplified. Check out our Media Kit for more information.

tiktok mba intern day in the life kearney media kit charu strategic operations

Bhakti Charu Swamis Vyasa Puja Glorification

Sacinandana Swamis Podcast

Play Episode Listen Later Oct 5, 2023 35:28

2023.09.17 Radhadesh EN

glorification bhakti puja charu vyasa swamis

Bhakti Charu Swamis Vyasa Puja Glorification

Sacinandana Swamis Podcast

Play Episode Listen Later Oct 5, 2023 35:28

2023.09.17 Radhadesh EN

glorification bhakti puja charu vyasa swamis

2023 Research Round Up: Lung Cancer

Cancer.Net Podcasts

Play Episode Listen Later Sep 28, 2023 31:20

ASCO: You're listening to a podcast from Cancer.Net. This cancer information website is produced by the American Society of Clinical Oncology, known as ASCO, the voice of the world's oncology professionals. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guests' statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Cancer research discussed in this podcast is ongoing, so data described here may change as research progresses. The theme of the 2023 ASCO Annual Meeting was “Partnering With Patients: The Cornerstone of Cancer Care and Research.” From June 2 to 6 in Chicago, Illinois, and online, cancer researchers and clinicians from around the world gathered to discuss the latest cancer research and how to ensure that all people receive the cancer care they need. In the Research Round Up series, members of the Cancer.Net Editorial Board discuss the most exciting and practice-changing research in their field presented at the meeting and explain what it means for people with cancer. In today's episode, our guests will discuss new research advances in treating non-small cell lung cancer, small cell lung cancer, and mesothelioma. Dr. Charu Aggarwal is the Leslye Heisler Associate Professor of Medicine in the Hematology-Oncology Division at the University of Pennsylvania's Perelman School of Medicine in Philadelphia, Pennsylvania. She is also the 2023 Cancer.Net Associate Editor for Lung Cancer. Dr. Melina Marmarelis is an assistant professor at the University of Pennsylvania, the Medical Director of the Penn Medicine Mesothelioma Program, and the co-director of the Molecular Tumor Board at the University of Pennsylvania. She is also the 2023 Cancer.Net Specialty Editor for Mesothelioma. Dr. Kristin Higgins is a radiation oncologist, Professor and Vice Chair in Clinical Research in the Department of Radiation Oncology at Emory University School of Medicine and medical director of radiation oncology of The Emory Clinic at Winship Cancer Institute's Clifton campus location. She is also a 2023 Cancer.Net Advisory Panelist for Lung Cancer. You can view disclosures for Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins at Cancer.Net. Dr. Aggarwal: Hello and welcome to this Cancer.Net Research Round Up podcast. Today, we will be talking about the latest research from the Annual Meeting of the American Society of Clinical Oncology from June 2023, and I'm joined today by 2 experts in the field of lung cancer. Before I introduce them, I'd like to introduce myself. I'm Dr. Charu Aggarwal. I'm an associate professor for lung cancer excellence at the University of Pennsylvania's Abramson Cancer Center. I'd now like to introduce Dr. Melina Marmarelis. Dr. Marmarelis: Hi, so happy to be here. I'm Melina Marmarelis. I'm an assistant professor at the University of Pennsylvania and the medical director of the Penn mesothelioma program. Dr. Aggarwal: And Dr. Kristin Higgins. Dr. Higgins: Hi, everyone. I'm Kristin Higgins. I am a thoracic radiation oncologist at Winship Cancer Institute of Emory University. I'm a professor and vice chair for clinical research for radiation oncology. Dr. Aggarwal: Fantastic. So today, we'll talk about relevant research as it applies to practical implications in the clinic for practitioners, but most importantly, patients with lung cancer. I'd like to start off by discussing 2 key studies, and I would love for perspectives from our faculty here. The first study I want to highlight is the ADAURA trial. This is a trial that has already sort of changed practice in most recent years when the study was presented at the Annual Meeting of the American Society of Clinical Oncology in 2020, but we have new updates on this study as of 2023. So, in brief, this was a study that looked at the value of administering an oral pill called osimertinib that is a tyrosine kinase inhibitor against the EGFR, or the epidermal growth factor receptor, in patients with non-small cell lung cancer. We know that non-small cell lung cancer is quite a heterogeneous disease with some subsets of patients having mutations that may render them increasingly sensitive to the effects of these tyrosine kinase inhibitors. In fact, these pills have been used in the metastatic setting for several years based on an improvement in overall survival. What the ADAURA study tried to do was ask the question if this pill would add an incremental advantage after receiving curative-intent surgical resection in those with early-stage lung cancer. So this study enrolled patients with stage IB to IIIA non-small cell lung cancer after surgical resection and focused only on those patients that had sensitizing EGFR mutations with EGFR exon 19 deletion or L858R mutations. Patients could receive chemotherapy after having the surgery and then were basically randomized into 2 groups, one of whom received osimertinib at a dose of 80 milligrams once daily for a total of 3 years. Patients were followed up for recurrence. We already know from the earlier results that patients who received osimertinib had a better chance of delaying the recurrence of disease. However, what we found at the Annual Meeting this year is that the administration of this osimertinib also improved overall survival, which is really what we all look for in the oncology world. If you're administering a therapy, especially for a long duration, we want to be able to see a survival benefit, and that's what we saw. In fact, in patients who received osimertinib, there was a 49% less likelihood of dying from lung cancer compared to those who did not receive osimertinib. This, I think, is practice-affirming. It may not be practice-changing because some of the practitioners started using osimertinib after its FDA approval in December of 2020, but I think it just confirms our practice as it delivers an overall survival advantage in these patients. One thing that's increasingly important is to identify patients who have this mutation, so now we have efforts underway locally as well as nationally to perform molecular genotyping on all patients with lung cancer so that we can adequately and appropriately treat those with early-stage lung cancer following curative resection or following surgery. Melina and Kristin, what are your thoughts? Dr. Marmarelis: Well, I think these results are really important because it did, as you say, affirm kind of what we're already doing, but I think the most convincing part of this for me is the prevention of spread of disease to the brain. This is not comparing osimertinib after surgery versus osimertinib ever, which I think is a difficult part about interpreting this trial. But I think the fact that it prevented disease from going to the brain is really meaningful to everyone, to patients, to the physicians that are caring for them, so I think that's a really important endpoint. Dr. Higgins: I agree with Melina. I think this is really exciting for our patients. It's exciting to have more treatment options for early-stage lung cancer. I think patients that are diagnosed with early-stage lung cancer are highly motivated to do everything they can to improve their likelihood of being cured. So I tend to have a lot of conversations about side effects and toxicities with patients that have questions and are sort of wondering how it will affect their quality of life, and of course, that is an important piece of it because patients that do have curable lung cancer are probably starting off with a better overall quality of life, but I think generally speaking, our patients have tolerated it well. I'm also kind of excited from a radiation oncology point of view. We treat patients with stereotactic body radiation therapy [SBRT] that are medically inoperable. And we have another trial with a cohort looking at osimertinib for those patients that have EGFR mutations, too, and that's ongoing, again, applying the same concept of trying to really use these SBRTs that work really well in the advanced setting, moving them into earlier stages of disease to help us care for more patients. So overall, I think it's really exciting, and I think it's a huge win for the clinical research community. Dr. Aggarwal: Well, that's wonderful. And I think this certainly advances the field as this is the first targeted therapy approved for patients with early-stage non-small cell lung cancer. I should add that AstraZeneca, the company that makes this drug, has provided institutional research funding to my institution, and I also serve as an advisor to them, but I was not involved personally in the research of this clinical trial. I'd like to move on but stay within the field of early-stage lung cancer and talk about another study called the KEYNOTE-671 study, and this is important because it really applies the idea of using immunotherapy before and after surgical resection in patients with early-stage lung cancer. Just to give a little bit of background to our listeners, we now have 3 approvals for the use of immunotherapy in patients with early-stage lung cancer. Two of those are in the adjuvant setting, meaning that if a patient undergoes surgical resection or surgery for early-stage lung cancer, they can receive either atezolizumab or pembrolizumab following that surgery, and that has been shown to improve outcomes in terms of reducing the chances of recurrence. We also have another approval, which is the third approval in early-stage lung cancer, where 3 cycles of chemotherapy and immunotherapy are administered prior to surgery, also called as the neoadjuvant chemo-immunotherapy approach. This drug that has been approved in combination with chemotherapy is nivolumab, and this approval came from a clinical trial called CheckMate 816 that showed both that patients who received this neoadjuvant chemo-immunotherapy approach had a higher proportion of patients who had complete response or pathologic complete response in their tumors at the time of surgery and also showed that the chances of the disease coming back after surgical resection was much lower amongst those that had received this intervention. The current study, the KEYNOTE-671 study, builds upon this concept and adds both a before-surgery intervention as well as an after-surgery intervention. So what this study did was it enrolled patients with early-stage, stage II to IIIB non-small cell lung cancer, and patients in the intervention arm received 4 cycles of chemotherapy in combination with pembrolizumab, underwent surgery, and then received immunotherapy with pembrolizumab for up to 13 cycles. Patients in the control arm received only chemotherapy prior to surgery and then placebo for up to 13 cycles after. This was a large study with about 786 patients randomized, and what we found was that those patients that received the intervention had a much higher likelihood of remaining disease-free or event-free following surgical resection as well as in the early analysis, an improvement in overall survival with about a 27% reduction in the risk of death. So I do think that this is the first study that shows us that use of both neoadjuvant as well as adjuvant. So sort of this perioperative approach of using immunotherapy before and after surgical resection can actually lead to improved outcomes. This is ultimately what we want for our patients, improvement in overall survival, improvement in cure rates, etc. The study has been silent on the use of radiation therapy, although it has gone into details in terms of the kinds of surgery that was done. Kristin, what are your views about this? Dr. Higgins: I think postoperative radiation after resection for non-small cell lung cancer has sort of started to fall out of favor because of the Lung ART trial that was published in Europe, a randomized phase III trial that showed no differences in disease-free survival or overall survival. And that's not to say that there aren't more study questions on ways to give it safer and ways to incorporate radiation in with the chemo-IO approach, and there are some novel ways to do that, and we're going to see some data presented at the World Lung Cancer Conference looking at some of those novel approaches. But standardly, when patients receive neoadjuvant chemo-immunotherapy followed by surgery, we typically would not offer radiation. There are instances, though, when patients have positive margins, for example, and in that situation, it's sort of a discussion on a case-by-case basis. But ideally, we're hoping that most of these patients that go to surgery are able to get a complete resection, and that's really the key component of the decision-making for deciding if patients are eligible for this approach. Dr. Aggarwal: I agree. Melina, any additional thoughts on this trial? Dr. Marmarelis: I think it's an exciting trial for the reasons that you mentioned. I think it does bring up a number of questions about whether both neoadjuvant and adjuvant immunotherapy are needed. I tend to like the idea of having immunotherapy present when the tumor is present before surgery, so I like kind of having that on board, but I think we still don't know which is more important. Dr. Aggarwal: So it certainly raises many more questions, which hopefully will be answered in the future. KEYNOTE-671 trial was conducted by Merck that produces the drug Keytruda, or pembrolizumab. We have received institutional research funding for other trials. I was not personally involved in this clinical trial. I do serve as an advisor for Merck. I think we'll bring you more research from the ASCO Annual Meeting. And I'll turn it over to Dr. Marmarelis to discuss some more exciting research. Dr. Marmarelis: Thanks, Charu. So perhaps it's not surprising that one of the exciting things I picked from ASCO has to do with mesothelioma. And I just want to put into context a little bit about why this trial was important. This is IND227. It was a cooperative group trial done across Canada, France, and Italy, and this was chemotherapy plus or minus pembrolizumab in patients with pleural mesothelioma that did not undergo surgery. So this was their first treatment, and they were not undergoing surgery. And the reason this trial was important is that in the last few years, we had results from CheckMate 743, which was looking at IPI/NIVO, so a combination of immunotherapies versus chemotherapy. And there was an improvement in survival for those that received double immunotherapy, and that improvement was most pronounced in the non-epithelioid population, which is actually a smaller subset of pleural mesotheliomas. And so as we've seen in the lung when we look at immunotherapy versus chemo, it raises the question of whether combination immunotherapy plus chemotherapy would actually be better for all and, in particular, for all histologies in pleural mesothelioma. So this was looking at that concept. It took the standard chemotherapy, carboplatin-pemetrexed or cisplatin-pemetrexed, and then combined it with one immunotherapy, so slightly less than the combo immunotherapy seen in CheckMate 743, and that was pembrolizumab. And what they saw was that there was a small overall survival improvement in the group that got pembrolizumab. Again, that was most pronounced in patients in the non-epithelioid group, so those with sarcomatoid or biphasic histology. And this is really a prelude to several other trials that are coming out in mesothelioma, namely the DREAM3R trial, which is looking at chemotherapy plus or minus durvalumab. That control arm also includes IPI/NIVO, so that will be really important to be able to compare those, and then also the BEAT-meso trial, which is looking at chemotherapy-immunotherapy but also with an anti-VEGF agent, bevacizumab. So I think this was an important trial. It's a little bit of proof of concept, but there's still a lot that we're looking forward to. It's not quite practice-changing in the clinic, although I think it's certainly an option that people are using, but I'm looking for more data going forward. Dr. Aggarwal: It's incredible to see how far we've come in mesothelioma within the last decade. We are introducing immunotherapy. We're introducing novel agents in the first-line setting. Dr. Marmarelis: The other trial that I was interested in was KEYNOTE-789, which is looking also at patients with EGFR mutations and those that had the original osimertinib as their first-line treatment or another tyrosine kinase inhibitor and then had disease progression on that TKI. And this is an area of huge need. We have patients that do really well on targeted therapies, and then they have disease progression, and we're looking for additional targeted options, but we're also looking for effective chemotherapy options. And one of the questions that has risen from this is whether there's a role for immunotherapy. We know that immunotherapy alone in patients with EGFR mutations is not very effective when you look at a broad population, but in combination with chemotherapy, it's possible that it can add some benefit. So this trial looked at those that had EGFR mutations, had disease progression after a targeted therapy, and then it randomized them to chemotherapy plus or minus pembrolizumab, so chemotherapy plus or minus immunotherapy, and interestingly, it had no difference in the progression-free survival or the overall survival. So the 2 arms were really similar in terms of outcomes. There was also no difference in the overall response rates of the amount that the drug actually shrinks the tumor. So it really doesn't look like immunotherapy is adding much to chemotherapy for these patients. I think we still need to look a little bit closer because there are probably some patients with EGFR mutations that could benefit from immunotherapy, but we're really not very good at identifying those. One of the questions that comes up in this space is whether to add anti-VEGF treatment in addition to chemotherapy and immunotherapy. So there are some upcoming trials looking at that. Dr. Aggarwal: I think this was a trial that was actually very important and again, practice-affirming that this idea of continuing chemotherapy without adding immunotherapy, patients are not losing much. In fact, they're not gaining anything by adding immunotherapy as shown in this clinical trial. I think continuing immunotherapy, so continuing osimertinib, may be important in this setting also because we know that osimertinib can cross the blood-brain barrier. It can provide that CNS [central nervous system] protection. Dr. Marmarelis: Yeah, I think that's a great point that the comparison here is not chemotherapy plus osimertinib. It's chemotherapy alone. So I agree that the control arm is not quite what some of us do. I agree. I do the same as you do. I also just want to mention that the KEYNOTE trial and the previous trial about mesothelioma used pembrolizumab, which is made by Merck. We have received institutional funding, and I've served as an advisor as well as received honorarium from Merck. Dr. Aggarwal: Melina, those were 2 very important studies and certainly, I think, answer some very relevant questions in clinic in the management of patients with EGFR-mutant lung cancer, for example. And then I think we look forward to more practice-changing data in mesothelioma. Kristin, I would love to hear research from ASCO from you. What caught your interest? Dr. Higgins: So I have a special interest in small cell lung cancer. And I think there was one important small cell lung cancer trial that I wanted to review with everyone. It was SWOG S1929. And SWOG is the Southwest Oncology Group, and it's a cooperative group that conducts clinical trials in cancer funded by the National Cancer Institute. And this is a randomized phase II trial of atezolizumab and chemotherapy followed by randomization to continuing the maintenance of atezolizumab with a PARP inhibitor. Now, we know from prior data that PARP inhibition is attractive for small cell lung cancer because PARP is expressed frequently in small cell lung cancer, and there is a biomarker called Schlafen-11 that preclinical data and prior data has shown can predict response to PARP inhibition. And this trial was sort of a proof-of-concept trial, a small, randomized phase II trial testing whether or not that Schlafen-11 biomarker could be used to direct therapy. Now, in this trial, there were 309 patients that were registered. They then had to have their tumor samples sent for central testing for the Schlafen-11 expression. One thing that I think is important to bring up is that in small cell lung cancer, there's this belief that it's really hard to get tissue samples from small cell lung cancer and it's a difficult thing logistically because it's just a lot harder to access these tumors. But interestingly, in this trial, 80% of patients had tumors that were evaluable for the biomarker, and the median time to the test result was only 7 days. So patients were able to get their tumor tested, get it sent out, get results in a rapid manner, and then be randomized based on these results. The primary endpoint for this trial was progression-free survival, and the primary endpoint was met. Progression-free survival was 4.2 months versus 2.8 months. Now, I think many people will say the magnitude of benefit here is not very much, but it's small cell lung cancer, and we don't have a lot of positive trials in this space, and we also don't have many trials that have used a biomarker to direct therapy. So I think for those reasons, it's really exciting to see these results. It was also conducted within a cooperative group with multiple different sites across the United States, and the fact of the matter is that we can do trials like this in small cell lung cancer patients, and I think it will sort of serve as a precedent for future trial design. Now, the overall survival for the trial is still premature. It didn't look that much different with the PARP inhibitor, but that doesn't mean that, again, things could change with more follow-up. And I really like the approach of this trial design, and I'm excited to see biomarker-driven trials in small cell lung cancer. Charu and Melina, what do you guys think about this study? And what do you think about our small cell lung cancer patients and our ability to conduct future trials like this? Dr. Aggarwal: I think this is certainly an advance. As you pointed out, Kristin, it shows us that we can conduct trials in the space. I think it offers a lens into the potential of personalized therapy in small cell lung cancer, which has eluded us for a very long time. The standard of small cell lung cancer has not changed significantly for a very long time, so I think this is very exciting and can't wait to see more things come in the future. Dr. Marmarelis: Yeah, I agree. I think we've always been asking for additional biomarkers, especially in such a difficult disease like small cell. And so this is really exciting to see potential biomarkers and that it was feasible to actually pose that question and study it. So that part's really exciting. Dr. Higgins: Great. And I should also say I was not involved in the study, and I'm not associated with any of the pharmaceutical companies that were involved in the study for S1929. And the final study that we wanted to talk about was the phase III LUNAR study, and this is sort of a different type of trial in the setting of advanced non-small cell lung cancer. It was studying tumor treatment fields with standard of care in metastatic non-small cell lung cancer after progression with platinum-based therapies. And first, I just want to step back and explain what tumor treating fields are. Tumor treating fields are applied to a patient with a transducer that's placed on the skin, and what it does is it applies an electrical field, and that disrupts mitosis when the cancer cells are trying to divide. And the mechanism of cell death is a little bit unclear. There are sort of many mechanisms that are postulated, one of which is immunogenic cell death, but we don't really know, I think, what's happening. But there have been studies that show improved results with tumor treating fields and other diseases. For example, particularly in glioblastoma multiforme, tumor treating fields are used in combination with surgery, radiation, and temozolomide (Temodar). So it's something that's being used in other disease sites, and this is some of the early data that we've seen in metastatic non-small cell lung cancer. And so in this trial, 276 patients were randomized to tumor treating fields plus standard of care or standard of care alone. Now, I should mention that this trial began enrolling patients in 2016, and so the standard of care was very different. After platinum-based therapies, the standard was considered docetaxel. Of course, platinum-based therapy alone for frontline treatment of advanced non-small cell lung cancer is also not the standard of care anymore. And so I think with that in the background, it does make interpretation of these results somewhat difficult, and that's probably the major caveat to this study. But nonetheless, patients were randomized, 276 patients. The primary endpoint of the study was overall survival. They were looking at progression-free survival and overall response rates as secondary endpoints as well as overall survival in patients that received immunotherapy versus just chemotherapy alone. And the trial was positive. Overall survival was improved. The median overall survival was 13.2 months for patients that received tumor treating fields with standard of care versus 9.9 months for standard of care alone. If you look at 3-year survival, it was 18% versus 7%. I think this is a new type of therapy for our patients with non-small cell lung cancer. It is somewhat of a difficult thing to wear the transducer, and you have to wear it for many, many hours. So that is one thing that I think can be difficult for patients that are using this treatment, but nonetheless, it is something new for advanced non-small cell lung cancer. I do know that the technology of tumor treating fields is being studied in other settings for non-small cell lung cancer, for stage III non-small cell lung cancer, for example, and also in the frontline setting. I think this trial kind of speaks to the fact that the landscape of advanced non-small cell lung cancer is changing so rapidly, and when we're studying something novel, we have to make sure that we make these trials feasible for enrollment so that we can get them completed rapidly, and we can get a readout and it doesn't become obsolete based on this shift in the standard of care. So I think it just really kind of drives home that we need to make sure that we're taking that into account with trial design. It's not standard of care changing right now, but it'll be interesting to see how the data evolves over time. Melina, I'm interested to hear your point of view because I know that these can be used in mesothelioma, maybe not that frequently. What is your experience with tumor treating fields, if any? Dr. Marmarelis: Tumor treating fields are approved as a device in pleural mesothelioma in the first-line setting in combination with chemotherapy. They have been used off-label in other settings, but that's the device approval. The trial that looked at tumor treating fields in mesothelioma was a single-arm trial, so there was no control arm, and it was really actually just looking at the safety of the device. So I have not used it personally in mesothelioma, although I know of patients and I know of real-world studies looking at its use, and I think it's potentially an interesting modality of treatment, especially in combination with immunotherapy, given that it really doesn't have a lot of additive toxicity. But I think the question is really, which patients are benefiting from it, and which patients are able to actually wear the vest in the case of mesothelioma? Dr. Higgins: Yeah. Any thoughts, Charu? Dr. Aggarwal: I agree, and I think this is going to be largely driven by patient experience. I think this is going to be quite onerous to wear this, carry the suitcase, so I would be very interested in patient reported outcomes as well as patient experiences and stories, which will really drive our use here. Dr. Higgins: Yeah, that's a great point. I should say that this trial was sponsored by Novocure. My institution does have other Novocure studies underway, and we receive research funding, but I was not involved in the study, and I did not personally receive any research funding. Dr. Aggarwal: Thank you, Kristin. This has been a wonderful review of practice-changing and some promising research that came out of the ASCO Annual Meeting. I hope our listeners enjoyed it, and we'll be sure to update you with the next annual research conference. Thank you, everyone. ASCO: Thank you, Dr. Aggarwal, Dr. Marmarelis, and Dr. Higgins. You can find more research from recent scientific meetings at www.cancer.net. Cancer.Net Podcasts feature trusted, timely, and compassionate information for people with cancer, survivors, and their families and loved ones. Subscribe wherever you listen to podcasts for expert information and tips on coping with cancer, recaps of the latest research advances, and thoughtful discussions on cancer care. And check out other ASCO Podcasts to hear the latest interviews and insights from thought leaders, innovators, experts, and pioneers in oncology. Cancer.Net is supported by Conquer Cancer, the ASCO Foundation, which funds lifesaving research for every type of cancer, helping people with cancer everywhere. To help fund Cancer.Net and programs like it, donate at CONQUER.ORG/Donate.

Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

CME in Minutes: Education in Primary Care

Play Episode Listen Later Sep 5, 2023 16:27

Please visit answersincme.com/ZRV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, two experts in lung carcinoma discuss the latest data in first-line chemoimmunotherapy for non–small-cell lung cancer.Upon completion of this activity, participants should be better able to: Outline which patients might align with first-line chemoimmunotherapy regimens for advanced NSCLC; Review the clinical profiles of chemoimmunotherapy regimens in the first-line setting for the treatment of advanced NSCLC; and Translate the latest data informing the use of first-line chemoimmunotherapy regimens to individualized care of patients with advanced NSCLC.

tango outline translate chemotherapy immunotherapy combinations aggarwal md mph first line nsclc charu clinical implications eric k advanced nsclc charu aggarwal

Interview with Drs. Charu Aggarwal & Balazs Halmos: Adjunctive & Neoadjuvant Therapy for Lung Cancer

Caris Molecular Minute Podcast Series

Play Episode Listen Later Sep 1, 2023 32:25

Caris Precision Oncology Alliance™ Chairman, Dr. Chadi Nabhan, sits down with Dr. Charu Aggarwal, the Leslye M. Heisler Associate Professor for Lung Cancer Excellence at UPENN, and Dr. Balazs Halmos, Director, Thoracic Oncology at Montefiore. Together they discuss adjuvant and neoadjuvant therapy for resected non-small cell lung cancer (NSCLC). Topics discussed will include current treatment options, how treatment decision are made, and when treatment should be given. For more information, please visit: www.CarisLifeSciences.com/POA-Intro/

director therapy upenn lung cancer aggarwal nsclc montefiore charu neoadjuvant balazs adjunctive thoracic oncology chadi nabhan charu aggarwal

Lung Cancer ASCO 2023 Highlights with Dr. Charu Aggarwal

Oncology Brothers

Play Episode Listen Later Jun 22, 2023 18:30

Discussing Lung Cancer ASCO 2023 Highlights, focusing on practice-changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies: - ADAURA trial update with increased OS with adjuvant Osimertinib - KEYNOTE 789 - Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant - KEYNOTE 671 - Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC

director os associate professor covering keynote lung cancer asco aggarwal randomized egfr penn medicine nsclc charu tki adaura charu aggarwal pemetrexed

Historic Eight Documents - Charu Mazumdar

Foreign Languages Press - Audiobooks

Play Episode Listen Later Jun 20, 2023 76:04

Written between 1965 and 1967 at a time when the Communist movement in India was at a crossroads between parliamentarism and the path of the people's war, these Historic Eight Documents were the main ideological basis of the Naxalbari uprising. They continue to have a deep influence on those who persevered in waging this protracted struggle of over 50 years. --- Support this podcast: https://podcasters.spotify.com/pod/show/foreign-languages-press/support

historic communists documents charu

Stumped on tour: The Women's Premier League in Mumbai